Integrated Strategy of Network Pharmacological Prediction and Experimental Validation Elucidate Possible Mechanism of Bu-Yang Herbs in Treating Postmenopausal Osteoporosis via ESR1

Hanting Xia, Jiangyuan Liu, Wenlong Yang, Min Liu, Yunfeng Luo, Zhijun Yang, Jingbo Xie, Huiliang Zeng, Rui Xu, Houfu Ling, Qinghe Zeng, Huihui Xu, Liang Fang, Hongyu Wang, Peijian Tong, Hongting Jin, Fengyun YangFrontiers in Pharmacology 2021 · DOI

TL;DR

This study investigates the mechanism behind traditional Chinese "Bu-Yang" herbs for treating postmenopausal osteoporosis (PMOP). By combining network pharmacology with in vivo and in vitro experiments, they found that these herbs, specifically through a decoction (BYD), effectively improve bone density and microarchitecture by targeting the estrogen receptor 1 (ESR1) and activating the Wnt/β-catenin signaling pathway.

What Problem Does This Paper Address?

Postmenopausal osteoporosis (PMOP) is a significant health concern for women due to estrogen deficiency, leading to bone loss and increased fracture risk. While traditional Chinese medicine (TCM) has shown promise in treating PMOP, the complex nature of TCM formulas has made it challenging to pinpoint the exact active compounds and their mechanisms of action. Specifically, "Bu-Yang" herbs are frequently used and considered effective, but their precise pharmacological profiles remain unclear. This paper aims to bridge this knowledge gap by elucidating the molecular mechanisms by which Bu-Yang herbs combat PMOP.

Methods

The researchers employed a multi-faceted approach:

  • Literature Mining: A systematic review of existing literature was conducted to identify the most frequently used and effective TCM herbs for PMOP.
  • Network Pharmacology: This computational approach was used to predict potential drug targets and pathways associated with Bu-Yang herbs. This involved:
  • Identifying chemical compounds within the selected herbs.
  • Predicting potential targets for these compounds.
  • Analyzing protein-protein interactions (PPI) and identifying hub genes.
  • Performing Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis.
  • Molecular docking was used to predict the binding affinity of key compounds to the target receptor ESR1.
  • Experimental Validation:
    • Bu-Yang Decoction (BYD) Preparation: A decoction was prepared from the identified representative Bu-Yang herbs.
  • In Vivo Studies: An ovariectomized (OVX) rat model of PMOP was used to assess the therapeutic effects of BYD on bone mineral density (BMD) and bone microarchitecture. Serum markers of bone metabolism were also analyzed.
  • In Vitro Studies: Osteoblasts were used to evaluate the effects of BYD on cell proliferation, osteogenic differentiation (measured by alkaline phosphatase activity and alizarin red staining), and the activation of key signaling pathways.
  • Mechanism Confirmation: The role of ESR1 was investigated by using an ESR1 inhibitor (ICI182,780) in vitro to block its activity and observe the downstream effects.
  • Molecular Techniques: Western blotting and RT-PCR were used to analyze the expression levels of key proteins and genes involved in osteogenesis and signaling pathways.

Datasets

  • Databases for Network Pharmacology:
    • TCMSP, ETCM, SYMMAP, BAT-MAN (for chemical compounds and targets of TCM herbs)
    • Genecards, OMIM (for PMOP disease-related genes)
    • PubChem (for 3D molecular structures)
    • STRING (for PPI analysis)
    • DAVID (for GO and KEGG enrichment analysis)
    • DrugBank (for FDA-approved drugs and their targets)
  • Experimental Data:
    • Data from OVX-induced PMOP rat models.
  • Data from cultured osteoblasts.

Key Insights and Ideas

  • Bu-Yang Herbs as a Promising Class: The literature review strongly indicated that Bu-Yang herbs are the most frequently used and effective TCM category for treating PMOP.
  • ESR1 as a Central Target: Network pharmacology consistently pointed to Estrogen Receptor 1 (ESR1) as a key target for Bu-Yang herbs in PMOP treatment. This aligns with the known role of estrogen deficiency in PMOP.
  • Wnt/β-catenin Pathway Activation: The study revealed that BYD not only acts via ESR1 but also activates the Wnt/β-catenin signaling pathway, which is crucial for bone formation.
  • Synergistic Action of Herbs: The use of a decoction (BYD) from multiple Bu-Yang herbs suggests a synergistic effect, where the combined action is more potent than individual herbs.
  • Natural Phytoestrogen Potential: The observed estrogen-like effects of BYD, coupled with the identification of compounds like quercetin and kaempferol, suggest that these herbs may contain natural phytoestrogens that mimic estrogen's beneficial effects on bone.

Key Results

  • In Vivo Efficacy: BYD treatment in OVX rats significantly reversed osteoporosis by increasing bone mineral density (BMD) and improving bone microarchitecture in a dose-dependent manner. The high dose of BYD showed comparable efficacy to β-estradiol.
  • In Vitro Efficacy: BYD enhanced osteoblast proliferation, alkaline phosphatase (ALP) activity, and mineral nodule formation.
  • Mechanism Validation: Inhibition of ESR1 with ICI182,780 blocked the osteogenic effects of BYD in vitro, confirming ESR1's critical role.
  • Signaling Pathway Activation: BYD treatment led to the upregulation of ESR1, β-catenin, and cyclinD1 at both mRNA and protein levels, and promoted the nuclear translocation of β-catenin, indicating Wnt/β-catenin pathway activation.

Limitations and Future Work

  • Chemical Compound Identification: While LC-MS identified some key compounds in BYD, a comprehensive analysis of all active constituents and their specific contributions is still needed.
  • Clinical Translation: The study was conducted in animal models and in vitro. Further clinical trials are necessary to confirm the safety and efficacy of BYD in human patients with PMOP.
  • Long-Term Effects: While the study demonstrated short-term benefits, long-term studies would be valuable to assess sustained effects and potential side effects.
  • Exact Chemical Compounds: The authors suggest further research to pinpoint the exact chemical compounds within BYD responsible for its therapeutic effects and to explore their potential for clinical use.

Summary updated

Abstract

Postmenopausal osteoporosis (PMOP) is a type of bone metabolism disease-related to estrogen deficiency with an increasing incidence. Traditional Chinese (TCM) has always been used and showed effectiveness in treating PMOP. In the current study, Bu-Yang herbs were considered to be the most frequently used and efficient TCM herbs in PMOP treatment. However, chemical and pharmacological profiles were not elucidated. Network pharmacology was conducted on representative Bu-Yang herbs (Yin-Yang-Huo. Du-Zhong, Bu-Gu-Zhi, Tu-Si-Zi) to investigate the mechanism of Bu-Yang herbs on PMOP. Chemical compounds, potential targets, and disease related genes were available from the corresponding database. Results showed that Bu-Yang herbs could interact with ESR1 and estrogen signaling pathways. For further validation, the Bu-Yang decoction (BYD), formula consisted of the above-mentioned 4 Bu-Yang herbs was presented for experimental validation. In vivo , BYD significantly reversed ovariectomy (OVX)-induced osteoporosis progress in a dose-dependent manner by up-regulation of bone mineral density and amelioration of bone microarchitecture. In vitro , BYD dramatically improved the proliferation and mineral nodules formation of osteoblasts. Both in vitro and in vivo results illustrated that the phenotype change induced by BYD is correlated with up-regulated of ESR1 and activation of the β-catenin pathway. Meanwhile, inhibition of ESR1 by ICI182, 780 blocked the osteogenic phenotype and β-catenin pathway activation induced by BYD. In conclusion, the current study suggested that Bu-Yang herbs are the most useful TCM herbs in treating PMOP. Furthermore, the integrated strategy of network pharmacology prediction with experimental validation suggested that BYD exerted its anti-PMOP via ESR1 and the downstream mechanism might be activation of the β-catenin signaling pathway.
BibTeX
@inproceedings{xia2021integrated,
  author = {Hanting Xia and Jiangyuan Liu and Wenlong Yang and Min Liu and Yunfeng Luo and Zhijun Yang and Jingbo Xie and Huiliang Zeng and Rui Xu and Houfu Ling and Qinghe Zeng and Huihui Xu and Liang Fang and Hongyu Wang and Peijian Tong and Hongting Jin and Fengyun Yang},
  title = {{Integrated Strategy of Network Pharmacological Prediction and Experimental Validation Elucidate Possible Mechanism of Bu-Yang Herbs in Treating Postmenopausal Osteoporosis via ESR1}},
  booktitle = {Frontiers in Pharmacology},
  year = {2021},
  doi = {10.3389/fphar.2021.654714},
}
Figure